Pharmaceutical Technology

JUNE 6, 2023

Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. According to Globaldata, it is involved in 5 clinical trials, which are ongoing. Pharma Mar Overview Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer.

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Pfizer is headquartered in New York, the US.

Hormones 113

Hormones Contract Manufacturing Manufacturing Development 113

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Pfizer is headquartered in New York, the US.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

The Pharma Data

MARCH 23, 2023

The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.

Hormones 40

Hormones Trials Branding Development 40

Pharmaceutical Technology

FEBRUARY 18, 2023

According to Globaldata, it is involved in 24 clinical trials, of which 19 were completed, 2 are ongoing, 1 is planned, and 2 were terminated. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Hormones 100

Hormones Production Development Clinical Trials 100

The Pharma Data

MARCH 23, 2021

Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 Bagsværd, Denmark, 23 March 2021 – New results from the STEP phase 3a clinical trial programme demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 28, 2021

Recommendation supported Data From Phase 3 KEYNOTE-355 Trial. Merck is rapidly advancing a broad portfolio in gynecologic and breast cancers through an in depth clinical development program for KEYTRUDA and a number of other other investigational and approved medicines across these areas. About Triple-Negative carcinoma.

Hormones 52

Hormones Medicine Clinical Research Research 52

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Antibody 98

Antibody Marketing Drugs Licensing 98

The Pharma Data

NOVEMBER 11, 2021

Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Wegovy for chronic weight management in adults with obesity. mg is an analogue of the human glucagon-like peptide-1 (GLP-1) hormone.

Medicine 52

Medicine Hormones Production Trials 52

Delveinsight

JULY 30, 2020

The buildup in adrenal glands leads to the insufficient hormonal response, thus leading to several of the symptoms such as deficiency of steroid hormones (mainly cortisol and aldosterone), impaired cortisol secretion, and others that are harbingers of the disease. The disorder can occur at any stage of life and vary with severity.

Hormones 52

Hormones Marketing Gene Trials 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. In particular, AI bears vast potential for advancing radiology.

Radiology 52

Radiology Cardiology Development Production 52

XTalks

NOVEMBER 9, 2023

XTALKS WEBINAR: The Evolution of the Cardiovascular Clinical Development Landscape and Potential Role of GLP-1 RAs Live and On-Demand: Wednesday, December 6, 2023, at 11am EST (4pm GMT/UK) Register for this free webinar to learn about successful study outcomes in developing GLP1s to new therapeutic areas within cardiovascular medicine and more.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

Drug Discovery World

APRIL 10, 2024

Some of the current optimism may be related to the nearly two decades of experience we now have with certain incretin hormone therapies based on glucagon-like peptide receptor agonists (GLP-1 RA), which modulate appetite, satiation and food intake and have revolutionised treatment for type 2 diabetes.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Hormones 52

Delveinsight

AUGUST 2, 2020

Cachexia is observed as a result of underlying diseases, including cancer, AIDS, tuberculosis, chronic heart failure, hormonal deficiency, and others. Earlier clinical evidence showcased administration of the therapy resulted in a statistically significant and dose-proportional increase in body weight.

Marketing 94

Marketing Pharma Companies Development Hormones 94

The Pharma Data

APRIL 11, 2023

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program. Based on these data, a first-in-human trial with BAY 2965501 in patients with advanced solid tumors was initiated and is currently enrolling patients.

Research 40

Research Clinical Trials Clinical Trials Trials 40

pharmaphorum

DECEMBER 23, 2020

The American Society of Clinical Oncology (ASCO) annual conference was one of the highlights of the year in cancer research and the fact it was held virtually did not distract from some stunning clinical lung cancer trial results presented by AstraZeneca. months, compared with 6.7 months in patients treated with chemotherapy.

Marketing 97

Marketing Gene Silencing Gene Drugs 97

XTalks

NOVEMBER 19, 2021

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

The Pharma Data

OCTOBER 14, 2020

FDA approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy is based on the results from two randomized, controlled trials (HARMONY CTP and HARMONY 1) from the clinical development program for WAKIX. WAKIX may reduce the effectiveness of hormonal contraceptives. Adverse Reactions.

FDA Approval 52

FDA Approval Hormones Production Drugs 52

The Pharma Data

DECEMBER 15, 2020

The Phase III trial evaluated the use of the diabetes vaccine Diamyd ® , an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. STOCKHOLM , Dec.

Development 40

Development Insulin Drugs Clinical Trials 40

The Pharma Data

SEPTEMBER 16, 2020

New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating Gavreto TM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

OCTOBER 26, 2020

Demand for our products remains robust, and production, supply and distribution of our medicines, vaccines and animal health products are moving forward with minimal disruption,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “I Oncology Pipeline Highlights.

Sales 40

Sales Vaccination Vaccine Production 40

The Pharma Data

DECEMBER 9, 2020

To meet the increased demand, HALIX expands with two additional viral vector production, the company said. announced a research collaboration to develop hormone receptor antagonist (GHRA) peptides as potential treatments for acromegaly, a rare but serious endocrine disorder with significant unmet medical need.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

JANUARY 10, 2021

10, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, will provide an update on Vision 3×3 and the company’s 2021 key milestones at the 39 th Annual J.P. COPENHAGEN, Denmark, Jan.

Hormones 40

Hormones Clinical Development Clinical Trials Clinical Trials 40

The Pharma Data

MARCH 17, 2021

The data builds on the primary outcome analysis of the positive Phase 3 monarchE trial that previously showed Verzenio, in combination with ET, decreased the risk of breast cancer recurrence by 28.7 The monarchE trial is ongoing and patients will continue to be followed to assess safety, PROs and other endpoints. had fatal outcomes.

HR 52

HR Trials In-Vitro Manufacturing 52

Drug Discovery World

AUGUST 21, 2023

Diana Spencer investigates therapies in clinical development for triple-negative breast cancer and asks what future treatments might look like. However, because these cancers are not driven by any of the three molecules that can be blocked by targeted hormone receptor drugs, current treatment options are limited.

Protein 52

Protein Trials Clinical Trials Clinical Trials 52

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. Late Breaking Oral Presentation OALC01LB03. Abstract 2361. Hillier et al.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Development 52

Pharmaceutical Technology

MARCH 2, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase III for Bile Duct Cancer (Cholangiocarcinoma). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

FDA Approval 100

FDA Approval Containment Development Genome 100

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

The safety profiles of Opdivo and chemotherapy in this trial are reflective of the known safety profiles of Opdivo and chemotherapy in first-line gastric and esophageal cancers. The company remains blinded to data from this arm and the trial continues in follow-up to allow the data to mature. PRINCETON, N.J.–(

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 27, 2020

. As part of its broad development program, BeiGene expects to work with the NHSA for potential NRDL inclusion in future expanded indications for these medicines. Complete approval for these indications may be contingent upon results from ongoing randomized, controlled confirmatory clinical trials. QARZIBA ® ?

Production 52

Production Drugs Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

The ultimate goal of the project is to present techniques and strategies general enough to be applied and scaled up in production facilities across industries. The ultimate goal of the project is to present techniques and strategies general enough to be applied and scaled up in production facilities across industries. STOCKHOLM , Dec.

Production 52

Production Insulin Vaccination Vaccine 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. 1. -- -->. -- [if lte IE 8]--> . adults age 65 and older.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. Mainly you see an improvement in complications such as diabetes, because these hormones are acting on the appetite and also in glucose levels. million in Q3.

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. Mainly you see an improvement in complications such as diabetes, because these hormones are acting on the appetite and also in glucose levels. million in Q3.

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246